Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
Co-Diagnostics, Inc. (CODX) reported a Q3 loss of $0.32 per share, slightly better than the Zacks Consensus Estimate of a $0.33 loss. However, this is a larger loss compared to $0.20 per share a year ago.
November 07, 2024 | 11:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Co-Diagnostics, Inc. reported a Q3 loss of $0.32 per share, which is slightly better than the expected loss of $0.33 per share. However, the loss is larger compared to the previous year's $0.20 per share.
The company's earnings per share loss was slightly better than expected, which is a positive sign. However, the loss is larger than the previous year, indicating potential challenges. This mixed result may lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100